An interventional study of physical exercise program and usual care in Polycystic Ovary Syndrome, Non-Alcoholic Fatty Pancreatic Disease and Subclinical hypothyroïdism, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-05-15.
Sponsored by Cairo University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Polycystic Ovary Syndrome by Cairo University — 10 open to participants now, 10 under way, none of them phase 3. Polycystic Ovary Syndrome · Cairo University.
Among the 34 studies in Polycystic Ovary Syndrome by Cairo University, this one is the 17th largest by planned enrollment of the 26 interventional ones that give a count, is one of 4 that started in 2026, is one of 20 with no phase, and was the 32nd registered.
959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.
Browse Polycystic Ovary Syndrome studies →10 of the 34 studies in Polycystic Ovary Syndrome by Cairo University are open now, in 1 country. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 20–30 · Women only
Cairo University · Sites in Egypt
Ages 30–40 · Women only
Cairo University · Sites in Egypt
Ages 35–45 · Women only
Cairo University · Sites in Egypt
Ages 18–35 · Women only
Cairo University · Sites in Egypt
Ages 20–35 · Women only
By country, each count listing its studies:
Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.
This study: 20 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 70 across 700 interventional studies indexed under Polycystic Ovary Syndrome.
Median enrollment 55 across the 26 interventional studies, 98 across the 8 observational. Of the 17 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
Cairo University is the lead sponsor of 4,967 studies on the registry; 1,474 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
3 of the studies in Polycystic Ovary Syndrome by Cairo University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07591246Cairo UniversityEfficay of Physical Activity Program in PCOS Females With Fatty Pancrease and Thyroid Hypofunction | 2026-12-30 |
| NCT07708766Cairo UniversityEffect of High Intensity Interval Training on Insulin Resistance in Polycystic Ovarian Syndrome | 2027-01-15 |
| NCT07937202Cairo UniversityEffects of Pilates Exercises on Doppler Parameters in Obese Females With Polycystic Ovarian Syndrome | 2027-04-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 34 studies in Polycystic Ovary Syndrome by Cairo University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism)
females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism) will be divided to groups (twenty female for the group). groups will be treated with levothyroxine and metformin, but one of these groups will perform aerobic treadmill walking.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
twenty females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism)will be treated with daily dose of levothyroxine in addition to daily twotimes of 500-mg metformin, and these females will perform 50 minutes of aerobic treadmill walking hrice weekly for six month.
Behavioral: physical exercise program
twenty females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism)will be treated with daily dose of levothyroxine in addition to daily twotimes of 500-mg metformin for six month
Other: usual care
twenty females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism)will be treated with daily dose of levothyroxine in addition to daily twotimes of 500-mg metformin, and these females will perform 50 minutes of aerobic treadmill walking hrice weekly for six month.
twenty females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism)will be treated with daily dose of levothyroxine in addition to daily two times of 500-mg metformin for six month.
Dehydroepiandrosterone
it is a hormone involved in synthesis of sex hormones
Time frame: it will be measured after 6 months
ratio of leutinzing hromone to hormone of follicels stimulatting hormones
this ration express level of sex hormone
Time frame: it will be measured after 6 months
testesterone
it is a sex horomone
Time frame: it will be measured after 6 months
body mass index
it will be assessed on empty stomach and bladder
Time frame: it will be measured after 6 months
waist circumference
it will be assessed on umblical levels
Time frame: it will be measured after 6 months
blood gluocose
it will be assessed in fasting status
Time frame: it will be measured after 6 months
glycated hemoglubin
it is an indiactor for longterm satus of blood gloucose
Time frame: it will be measured after 6 months
insulin
it will be assessed in plasma
Time frame: it will be measured after 6 months
thyroid stimualtined horomone
it will be assessed in plasma
Time frame: it will be measured after 6 months
triglyceridess
it will be assessed in plasma
Time frame: it will be measured after 6 months
low densitiy liopporotein
it will be assessed in plasma
Time frame: it will be measured after 6 months
cholesteroll
it will be assessed in plasma
Time frame: it will be measured after 6 months
high densitiy lipoporteins
it will be assessed in plasma
Time frame: it will be measured after 6 months
alanine transaminase
it will be assessed in plasma
Time frame: it will be measured after 6 months
aspartatte transaminase
it will be assessed in plasma
Time frame: it will be measured after 6 months
Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.
Of 205 non-industry interventional studies with no phase under Polycystic Ovary Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 9 months is below that.
Counting every sponsor, half of 220 studies reached it within 17 months; a quarter within 7 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.